Fremanezumab: clinical trials recruiting now
3
Recruiting trials
6
Conditions studied
0
US states with sites
3
Countries
FDA drug label
- FDA-approved
- Yes. Fremanezumab appears in the FDA drug-label database. Marketed as AJOVY.
FDA-approved use
AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )
Phase breakdown
Not applicable 3
Conditions being studied
| Condition | Trials |
|---|---|
| Migraine · Fremanezumab for Migraine | 3 |
| Anxiety | 1 |
| Chronic Migraine | 1 |
| Depression | 1 |
| Episodic Migraine | 1 |
| Menstrual Migraine | 1 |
Recruiting trials involving Fremanezumab
- CGRP Inhibition, Autonomic Function, and Migraine
- Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
- Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
Common questions
Is Fremanezumab FDA-approved?
Yes, marketed as AJOVY.
How many recruiting trials involve Fremanezumab?
3 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.